Drug Profile
Pancrelipase - Johnson & Johnson Innovative Medicine
Alternative Names: PancreazeLatest Information Update: 10 Oct 2023
Price :
$50
*
At a glance
- Originator Ortho-McNeil-Janssen Pharmaceuticals
- Developer VIVUS
- Class Pancreatic enzymes
- Mechanism of Action Pancrelipase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Exocrine pancreatic insufficiency
Most Recent Events
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 05 Feb 2020 The US FDA approves supplemental New Drug Application to extend the shelf life to 36 months across all pancrelipase dosages for Exocrine pancreatic insufficiency
- 26 Jun 2019 VIVUS amends its manufacturing and supply agreement with Nordmark Arzneimittel to co-develop additional pancrelipase dose formulations